The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic
engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy …

T cells in the immune system protect the human body from infection by pathogens and clear
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …

Variable domains of heavy chain-only antibodies (VHH), also known as nanobodies (Nbs),
are monomeric antigen-binding domains derived from the camelid heavy chain-only …

Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved remarkable success in some …

Targeted therapy and immunotherapy have become mainstream in cancer treatment.
However, only patient subsets benefit from these expensive therapies, and often responses …

Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy
with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) …

The development of monoclonal antibody treatments for successful tumor-targeted therapies
took several decades. However, the efficacy of antibody-based therapy is still confined and …

Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the
present immunotherapy era, several immunotherapeutic agents have been evaluated in …

Simple Summary Prostate cancer is one of the most frequently diagnosed cancers amongst
men worldwide. Treatment for metastatic disease is often in the form of androgen deprivation …